You are here

The Regents of the University of Michigan

Fleming Administration Bldg, 503 Thompson St
Ann Arbor, MI 48109
United States

Radiotherapy is the only standard of care for H3K27M mutant diffuse midline glioma. Unfortunately, following initial response tumors recur. Experimental therapeutics can synergize with radiotherapy to produce a greater therapeutic effect than either agent alone, a concept known as 'radiosensitization'. Our team has pioneered this concept both in the laboratory and clinic including in successful bench-to-bedside translational studies in patients with brain tumors.

Radiation is the primary treatment for diffuse midline gliomas (DMGs). Unfortunately, the vast majority of these tumors recur within the radiation treatment field owing to the inherent resistance of these tumors to radiotherapy. Given that radiation kills tumor cells by inducing DNA double strand breaks (DSBs), experimental therapeutics which target the DNA damage response are promising strategies for improving radiation therapy outcomes.

Chromosomal translocations of the nucleoporin 98 (NUP98) genes, which lead to the expression of NUP98 fusion proteins, are often found in patients with various hematologic malignancies, but are particularly prevalent in pediatric acute leukemia, constituting ~10% of all childhood leukemia cases. The presence of NUP98 translocations in pediatric leukemia patients confers very poor clinical outcome, leading to only ~10% of event-free survival three years after diagnosis and <30% four years survival rate.

Our research project will investigate the association of a very frequent mutation in DIPG tumor cells with proteins that help to establish the structure of DNA. Elevated expression of these proteins seems to affect the normal function of DNA and may result in abnormal cell growth. Our goal is to inhibit these DNA proteins to specifically target the potential cause contributing to the maintenance of DIPG cells.

Mentor: Costas Lyssiotis